
Don P. Le
Examiner (ID: 8344, Phone: (571)272-1806 , Office: P/2844 )
| Most Active Art Unit | 2819 |
| Art Unit(s) | 2819, 2844 |
| Total Applications | 2669 |
| Issued Applications | 2528 |
| Pending Applications | 46 |
| Abandoned Applications | 99 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19318363
[patent_doc_number] => 20240239906
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-18
[patent_title] => METHOD OF MODIFYING ISOELECTRIC POINT OF ANTIBODY VIA AMINO ACID SUBSTITUTION IN CDR
[patent_app_type] => utility
[patent_app_number] => 18/432567
[patent_app_country] => US
[patent_app_date] => 2024-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 93259
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18432567
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/432567 | Method of modifying isoelectric point of antibody via amino acid substitution in CDR | Feb 4, 2024 | Issued |
Array
(
[id] => 19521131
[patent_doc_number] => 12122840
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-22
[patent_title] => Method of modifying isoelectric point of antibody via amino acid substitution in CDR
[patent_app_type] => utility
[patent_app_number] => 18/425859
[patent_app_country] => US
[patent_app_date] => 2024-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 62
[patent_figures_cnt] => 64
[patent_no_of_words] => 93131
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 77
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18425859
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/425859 | Method of modifying isoelectric point of antibody via amino acid substitution in CDR | Jan 28, 2024 | Issued |
Array
(
[id] => 19504999
[patent_doc_number] => 12116410
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-10-15
[patent_title] => Methods of manufacturing dimeric antibodies
[patent_app_type] => utility
[patent_app_number] => 18/396466
[patent_app_country] => US
[patent_app_date] => 2023-12-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 7
[patent_no_of_words] => 16302
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 311
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18396466
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/396466 | Methods of manufacturing dimeric antibodies | Dec 25, 2023 | Issued |
Array
(
[id] => 19519888
[patent_doc_number] => 12121587
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-10-22
[patent_title] => Dimeric antibodies
[patent_app_type] => utility
[patent_app_number] => 18/396418
[patent_app_country] => US
[patent_app_date] => 2023-12-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 7
[patent_no_of_words] => 16306
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 420
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18396418
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/396418 | Dimeric antibodies | Dec 25, 2023 | Issued |
Array
(
[id] => 19201506
[patent_doc_number] => 20240173405
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-30
[patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-HUMAN TSLP RECEPTOR ANTIBODIES AND METHODS OF USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 18/503245
[patent_app_country] => US
[patent_app_date] => 2023-11-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 154742
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18503245
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/503245 | Pharmaceutical compositions comprising anti-human TSLP receptor antibodies and methods of using the same | Nov 6, 2023 | Issued |
Array
(
[id] => 18754005
[patent_doc_number] => 20230357367
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-09
[patent_title] => Antigen Binding Molecules Targeting SARS-CoV-2
[patent_app_type] => utility
[patent_app_number] => 18/314091
[patent_app_country] => US
[patent_app_date] => 2023-05-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 59496
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 115
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18314091
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/314091 | Antigen Binding Molecules Targeting SARS-CoV-2 | May 7, 2023 | Abandoned |
Array
(
[id] => 18754004
[patent_doc_number] => 20230357366
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-09
[patent_title] => Antigen Binding Molecules Targeting SARS-CoV-2
[patent_app_type] => utility
[patent_app_number] => 18/313306
[patent_app_country] => US
[patent_app_date] => 2023-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 59545
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 115
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18313306
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/313306 | Antigen binding molecules targeting SARS-CoV-2 | May 4, 2023 | Issued |
Array
(
[id] => 18643308
[patent_doc_number] => 11767368
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2023-09-26
[patent_title] => Antigen-binding protein and use thereof
[patent_app_type] => utility
[patent_app_number] => 18/061533
[patent_app_country] => US
[patent_app_date] => 2022-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 15623
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 130
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18061533
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/061533 | Antigen-binding protein and use thereof | Dec 4, 2022 | Issued |
Array
(
[id] => 18183650
[patent_doc_number] => 20230044380
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => LYMPHOCYTES-ANTIGEN PRESENTING CELLS CO-STIMULATORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/821182
[patent_app_country] => US
[patent_app_date] => 2022-08-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 79091
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 116
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17821182
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/821182 | Lymphocytes-antigen presenting cells co-stimulators and uses thereof | Aug 20, 2022 | Issued |
Array
(
[id] => 19550198
[patent_doc_number] => 12133890
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-11-05
[patent_title] => Antigen-binding polypeptide targeting B7H3 and application thereof
[patent_app_type] => utility
[patent_app_number] => 18/575650
[patent_app_country] => US
[patent_app_date] => 2022-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 51
[patent_no_of_words] => 31783
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 106
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18575650
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/575650 | Antigen-binding polypeptide targeting B7H3 and application thereof | Jun 29, 2022 | Issued |
Array
(
[id] => 18574258
[patent_doc_number] => 11730764
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-08-22
[patent_title] => Compositions and methods for treating HER2 positive cancers
[patent_app_type] => utility
[patent_app_number] => 17/809409
[patent_app_country] => US
[patent_app_date] => 2022-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 31
[patent_no_of_words] => 62698
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 228
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17809409
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/809409 | Compositions and methods for treating HER2 positive cancers | Jun 27, 2022 | Issued |
Array
(
[id] => 18004991
[patent_doc_number] => 20220363757
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-17
[patent_title] => ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/834497
[patent_app_country] => US
[patent_app_date] => 2022-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28683
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17834497
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/834497 | Anti-lag-3 antibodies and compositions | Jun 6, 2022 | Issued |
Array
(
[id] => 17505198
[patent_doc_number] => 20220098300
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-31
[patent_title] => ANTI TRBC1 ANTIGEN BINDING DOMAINS
[patent_app_type] => utility
[patent_app_number] => 17/499687
[patent_app_country] => US
[patent_app_date] => 2021-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10935
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17499687
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/499687 | Anti TRBC1 antigen binding domains | Oct 11, 2021 | Issued |
Array
(
[id] => 17843757
[patent_doc_number] => 11433099
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-06
[patent_title] => Immunotherapy with B*08 restricted peptides and combination of peptides against cancers and related methods
[patent_app_type] => utility
[patent_app_number] => 17/484452
[patent_app_country] => US
[patent_app_date] => 2021-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 44
[patent_figures_cnt] => 47
[patent_no_of_words] => 40233
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 91
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17484452
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/484452 | Immunotherapy with B*08 restricted peptides and combination of peptides against cancers and related methods | Sep 23, 2021 | Issued |
Array
(
[id] => 17577034
[patent_doc_number] => 20220133889
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-05
[patent_title] => COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3
[patent_app_type] => utility
[patent_app_number] => 17/478370
[patent_app_country] => US
[patent_app_date] => 2021-09-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 104890
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17478370
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/478370 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | Sep 16, 2021 | Abandoned |
Array
(
[id] => 17314522
[patent_doc_number] => 20210403570
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => ANTI-PD-1 ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/477889
[patent_app_country] => US
[patent_app_date] => 2021-09-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20331
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -40
[patent_words_short_claim] => 149
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17477889
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/477889 | ANTI-PD-1 ANTIBODIES AND USES THEREOF | Sep 16, 2021 | Abandoned |
Array
(
[id] => 17314469
[patent_doc_number] => 20210403517
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/471271
[patent_app_country] => US
[patent_app_date] => 2021-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 71020
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17471271
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/471271 | D-domain containing polypeptides and uses thereof | Sep 9, 2021 | Issued |
Array
(
[id] => 17312843
[patent_doc_number] => 20210401891
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/471206
[patent_app_country] => US
[patent_app_date] => 2021-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 71079
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17471206
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/471206 | D-domain containing polypeptides and uses thereof | Sep 9, 2021 | Issued |
Array
(
[id] => 18413182
[patent_doc_number] => 11667715
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-06-06
[patent_title] => Lym-1 and Lym-2 antibody compositions and improved car constructs
[patent_app_type] => utility
[patent_app_number] => 17/402300
[patent_app_country] => US
[patent_app_date] => 2021-08-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 30
[patent_figures_cnt] => 81
[patent_no_of_words] => 42439
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17402300
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/402300 | Lym-1 and Lym-2 antibody compositions and improved car constructs | Aug 12, 2021 | Issued |
Array
(
[id] => 17258537
[patent_doc_number] => 20210371522
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-02
[patent_title] => CD47 ANTIBODIES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/391888
[patent_app_country] => US
[patent_app_date] => 2021-08-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34998
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17391888
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/391888 | CD47 ANTIBODIES AND METHODS OF USE THEREOF | Aug 1, 2021 | Abandoned |